Figure 2.

Effect of AdipoRon on orthotopic tumour growth in DIO mice maintained on an HFD. (A) Schedule of the experiments and monitoring of body weight. DIO mice were intraperitoneally administered 5 mg/kg AdipoRon or vehicle every day for 10 days, and then the GTT and blood sampling were performed after overnight fasting. On day 11, Panc02-Luc-ZsGreen cells (2 × 10⁵ cells in 50% Matrigel) were injected into the pancreas. From day 13, the mice were intraperitoneally administered 5 mg/kg AdipoRon or vehicle every day until day 30. On day 23 and day 33, in vivo bioluminescent imaging was performed. (B) GTT performed on day 11 (n = 5 mice for each group). (C) Fasting glucose level (n = 5 mice for each group). Blood was collected on day 11 after fasting. (D) Fasting insulin level. Blood was collected on day 11 after fasting (n = 5 mice for each group). (E) HOMA-IR score calculated from the fasting glucose level and fasting insulin level in blood. (F) In vivo bioluminescent images. Orthotopic tumour growth in the vehicle- and AdipoRon-administered mice (n = 8 mice for each group) was assessed on day 23 (12 days after tumour implantation) and day 22 (22 days after tumour implantation). (G) Tumour growth on day 12 and day 22 represented by photons. Photons from animals’ whole bodies were imaged using the IVIS imaging system. (H) Tumours and tumour weight. Bar 1 cm. (I) Correlation between body weight and tumour weight. Blue and orange circles represent individual mice in the LFD and HFD groups, respectively. *P < 0.05, **P < 0.01, ns, not significant.